Robb Wesselingh
YOU?
Author Swipe
View article: Subjective neuropsychological deficits in autoimmune encephalitis: Patient-informant discrepancies and cognitive test outcomes
Subjective neuropsychological deficits in autoimmune encephalitis: Patient-informant discrepancies and cognitive test outcomes Open
Both patients and caregivers reported considerable neuropsychological impairments following AE, emphasising the ongoing burden of disease. Importantly, discrepancies between patient and informant perspectives illustrate the limitations of …
View article: 3617 Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitis
3617 Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitis Open
View article: 3588 CLOX and neurotox: utility of clock drawing to monitor immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy
3588 CLOX and neurotox: utility of clock drawing to monitor immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy Open
View article: CS5 Cognitive recovery following immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy
CS5 Cognitive recovery following immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy Open
View article: Subjective psychiatric symptoms in post-acute autoimmune encephalitis: findings from the Australian autoimmune encephalitis consortium
Subjective psychiatric symptoms in post-acute autoimmune encephalitis: findings from the Australian autoimmune encephalitis consortium Open
Background and objectives This study examined self-reported psychopathology in patients with autoimmune encephalitis (AE), and explored their relationship with clinical outcomes as measured by the modified Rankin Scale (mRS) and Clinical A…
View article: The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis Consortium
The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis Consortium Open
Background Patients with Autoimmune Encephalitis (AE) commonly report poor quality of life. There is a lack of evidence on whether clinician-rated outcome measures adequately capture patient-reported experiences. This study aimed to charac…
View article: Neurotoxicity associated with chimeric antigen receptor T-cell therapy
Neurotoxicity associated with chimeric antigen receptor T-cell therapy Open
Chimeric antigen receptor T cell (CAR-T) therapy involves reengineering patient-derived or donor-derived T cells to express a synthetic CAR that can recognise specific cell-surface antigens, independently of major histocompatibility comple…
View article: Indications and Diagnostic Yield of Paraneoplastic and Autoimmune Encephalitis Antibody Testing: A Retrospective Cohort Study
Indications and Diagnostic Yield of Paraneoplastic and Autoimmune Encephalitis Antibody Testing: A Retrospective Cohort Study Open
Background Autoimmune encephalitis (AE) and paraneoplastic syndromes (PNS) are rare disorders with distinct phenotypes. They are increasingly considered in patients with diverse neurologic symptoms, but the clinical context remains critica…
View article: <scp>CLOX</scp> and neurotox: Utility of the clock drawing task in monitoring for immune effector cell‐associated neurotoxicity syndrome following chimeric antigen receptor T‐cell therapy
<span>CLOX</span> and neurotox: Utility of the clock drawing task in monitoring for immune effector cell‐associated neurotoxicity syndrome following chimeric antigen receptor T‐cell therapy Open
Summary Immune effector cell‐associated neurotoxicity syndrome (ICANS)‐associated cognitive impairment is common in patients who receive chimeric antigen receptor T‐cell (CAR‐T) therapy. This study evaluated the utility of the clock drawin…
View article: Acute and Long-Term Immune-Treatment Strategies in Anti-LGI1 Antibody–Mediated Encephalitis
Acute and Long-Term Immune-Treatment Strategies in Anti-LGI1 Antibody–Mediated Encephalitis Open
This study provides Class IV evidence that for patients with anti-LGI1 Ab-mediated encephalitis, rituximab prevents relapses and acute methylprednisolone is associated with favorable outcomes at 12 months.
View article: Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis
Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis Open
This study provides Class IV evidence that rituximab delays relapses in patients with anti-NMDAR antibody-mediated encephalitis.
View article: Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium study
Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium study Open
Background and objectives To identify factors predictive of a favourable modified Rankin score (mRS) at 12 months in patients with autoimmune encephalitis (AE). To evaluate predictors of a binary composite clinical-functional outcome measu…
View article: Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case series
Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case series Open
Background Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common complication of chimeric antigen receptor (CAR) T-cell therapy. Current practice guidelines recommend the immune effector cell-associated encephalopathy …
View article: Memory function in autoimmune encephalitis: a cross-sectional prospective study utilising multiple memory paradigms
Memory function in autoimmune encephalitis: a cross-sectional prospective study utilising multiple memory paradigms Open
Background and objective Autoimmune encephalitis (AE) is often associated with clinically significant memory impairment. This study aimed to evaluate memory in a cross-sectional prospective AE cohort using multiple memory paradigms. Method…
View article: Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic
Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic Open
Background In Australia, tixagevimab/cilgavimab 150 mg/150 mg was a government-funded pre-exposure prophylaxis for COVID-19 people with multiple sclerosis (pwMS) and other neuroimmunological conditions (pwNIc) treated with anti-CD20 antibo…
View article: Clinical outcomes among initial survivors of cryptogenic new‐onset refractory status epilepsy ( <scp>NORSE</scp> )
Clinical outcomes among initial survivors of cryptogenic new‐onset refractory status epilepsy ( <span>NORSE</span> ) Open
Objective New‐onset refractory status epilepticus (NORSE) is a rare but severe clinical syndrome. Despite rigorous evaluation, the underlying cause is unknown in 30%–50% of patients and treatment strategies are largely empirical. The aim o…
View article: Language impairments in seropositive and seronegative autoimmune encephalitis
Language impairments in seropositive and seronegative autoimmune encephalitis Open
Background and objective Autoimmune encephalitis (AE) is a rare neuroinflammatory disease affecting the central nervous system. To examine language functions in patients with different subsets of AE consisting of seropositive and seronegat…
View article: Circulatory Immune Cell Counts and Clinical Outcomes in Multiple Sclerosis Relapse Versus Remission
Circulatory Immune Cell Counts and Clinical Outcomes in Multiple Sclerosis Relapse Versus Remission Open
View article: Investigating the Association Between Extended Participation in Collision Sports and Fluid Biomarkers Among Masters Athletes
Investigating the Association Between Extended Participation in Collision Sports and Fluid Biomarkers Among Masters Athletes Open
Traumatic brain injuries (TBIs) and concussions are prevalent in collision sports, and there is evidence that levels of exposure to such sports may increase the risk of neurological abnormalities. Elevated levels of fluid-based biomarkers …
View article: Neutropaenia complications from Ocrelizumab and Rituximab treatment
Neutropaenia complications from Ocrelizumab and Rituximab treatment Open
Ocrelizumab is an anti-CD20 monoclonal antibody (mAb) that has been shown in phase 3 clinical trials to reduce relapses and disease progression in multiple sclerosis (MS) patients. Prior to the approval of ocrelizumab, rituximab, a chimeri…
View article: Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study
Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study Open
Objective This study uses the Wechsler intelligence and memory scales to characterize the cognitive function of patients with autoimmune encephalitis (AE) in the chronic stage of the disease. AE is a group of neuroinflammatory disorders, a…
View article: Prevalence, pathogenesis and spectrum of neurological symptoms in <scp>COVID</scp>‐19 and <scp>post‐COVID</scp>‐19 syndrome: a narrative review
Prevalence, pathogenesis and spectrum of neurological symptoms in <span>COVID</span>‐19 and <span>post‐COVID</span>‐19 syndrome: a narrative review Open
Summary Neurological symptoms are not uncommon during severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and reflect a broad spectrum of neurological disorders of which clinicians should be aware. The underlying pathoge…
View article: 2808 Exploring the uptake, and real-world efficacy of intramuscular tixagevimab150mg/150mg cilgavimab (Evusheld<sup>TM</sup>) in multiple sclerosis patients (pwMS) during COVID 19 pandemic
2808 Exploring the uptake, and real-world efficacy of intramuscular tixagevimab150mg/150mg cilgavimab (Evusheld<sup>TM</sup>) in multiple sclerosis patients (pwMS) during COVID 19 pandemic Open
Background In Australia, Evusheld – (tixagevimab150mg and cilgavimab150mg) is currently the only pre-exposure prophylaxis for COVID-19 infection Persons with Multiple Sclerosis (pwMS) who are treated with anti-CD20 antibodies and sphingosi…
View article: 2785 Executive dysfunction in patients with autoimmune encephalitis – a study of Australian autoimmune encephalitis consortium
2785 Executive dysfunction in patients with autoimmune encephalitis – a study of Australian autoimmune encephalitis consortium Open
Objectives The objective of this study was to characterise executive functions (EF), and determine which aspects of EF are most affected in patients with Autoimmune Encephalitis (AE). Methods 52 patients who met the criteria for possible A…
View article: 2781 Memory outcomes in patients with autoimmune encephalitis – a study of the Australian autoimmune encephalitis consortium
2781 Memory outcomes in patients with autoimmune encephalitis – a study of the Australian autoimmune encephalitis consortium Open
Background & Objective Patients with autoimmune encephalitis (AE) can present with a variety of memory complaints. However, it is difficult to draw strong conclusions regarding memory as there has been significant heterogeneity in the asse…
View article: 7 CLADIN: CLADribine and INnate immune responses in multiple sclerosis
7 CLADIN: CLADribine and INnate immune responses in multiple sclerosis Open
Introduction Cladribine (Mavenclad®) is an oral treatment for relapsing remitting MS (RRMS). P2X7R is a purinergic receptor implicated in neuroinflammatory processes. Objective To investigate the mechanism of action of Cladribine on periph…
View article: An eye to the future: Acute and long‐term neuro‐ophthalmological and neurological complications of COVID‐19
An eye to the future: Acute and long‐term neuro‐ophthalmological and neurological complications of COVID‐19 Open
COVID‐19 has had a significant impact on the global population and has produced compelling evidence of non‐pulmonary organ dysfunction, including the nervous system. It is vital that specialists in ophthalmology and neurology are informed …
View article: 2330 Neuropsychological syndromes of autoimmune encephalitis – a retrospective study
2330 Neuropsychological syndromes of autoimmune encephalitis – a retrospective study Open
Objectives Despite the rapid increase in research examining outcomes in Autoimmune Encephalitis (AE) patients, there are few cohort studies examining cognitive outcomes in this population. Here, we conducted a retrospective observational s…
View article: 2339 Neuropsychological outcomes in chronic autoimmune encephalitis – A study from the Australian autoimmune encephalitis consortium
2339 Neuropsychological outcomes in chronic autoimmune encephalitis – A study from the Australian autoimmune encephalitis consortium Open
Objectives While cognitive dysfunction after autoimmune encephalitis (AE) is subjectively noted by patients and caretakers alike; objective neuropsychological assessments in chronic AE cohorts, are rarely reported. Methods Standardised neu…
View article: 2304 CLADIN: CLADribine and INnate Immune responses in Multiple Sclerosis
2304 CLADIN: CLADribine and INnate Immune responses in Multiple Sclerosis Open
Introduction Cladribine (Mavenclad®) is an oral treatment for relapsing remitting MS (RRMS). In RRMS clinical trials, Cladribine has been shown to reduce brain atrophy, relapse rates, and new lesions on MRI. Cladribine is thought to produc…